Abstract
A population-based retrospective chart review of the biochemical liver tests of 844 patients with multiple sclerosis prescribed a beta-interferon (IFNbeta) product in British Columbia, Canada was performed between 1995 and 2001. Overall, 36.9% (243/659) of patients developed new elevations of alanine aminotransferase. All the IFNbetas caused elevated aminotransferase levels compared with pretreatment levels (p < 0.005) and were higher than reported in clinical trials. Their relative effect on aminotransferases can be approximated as IFNbeta-1b(subcutaneous [SC]) = IFNbeta-1a(SC) > IFNbeta-1a(IM).
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adult
-
Alanine Transaminase / blood
-
Aspartate Aminotransferases / blood
-
Biomarkers
-
British Columbia / epidemiology
-
Chemical and Drug Induced Liver Injury, Chronic / epidemiology
-
Chemical and Drug Induced Liver Injury, Chronic / etiology*
-
Drug Monitoring
-
Female
-
Follow-Up Studies
-
Humans
-
Injections, Intramuscular
-
Injections, Subcutaneous
-
Interferon beta-1a
-
Interferon beta-1b
-
Interferon-beta / administration & dosage
-
Interferon-beta / adverse effects*
-
Interferon-beta / therapeutic use
-
Male
-
Middle Aged
-
Multiple Sclerosis / drug therapy*
-
Retrospective Studies
-
Risk Factors
Substances
-
Biomarkers
-
Interferon beta-1b
-
Interferon-beta
-
Aspartate Aminotransferases
-
Alanine Transaminase
-
Interferon beta-1a